$3.46
2.81% yesterday
NYSE, Sep 27, 10:00 pm CET
ISIN
US74168J1016
Symbol
PRME
Sector
Industry

Prime Medicine Target price 2024 - Analyst rating & recommendation

Prime Medicine Classifications & Recommendation:

Buy
83%
Hold
17%

Prime Medicine Price Target

Target Price $13.45
Price $3.46
Potential
Number of Estimates 11
11 Analysts have issued a price target Prime Medicine 2025 . The average Prime Medicine target price is $13.45. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 12 analysts: 10 Analysts recommend Prime Medicine to buy, 2 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Prime Medicine stock has an average upside potential 2025 of . Most analysts recommend the Prime Medicine stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 0.00 4.65

12 Analysts have issued a sales forecast Prime Medicine 2024 . The average Prime Medicine sales estimate is

$4.6m
Unlock
. This is
687.51% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$40.0m 6,679.66%
Unlock
, the lowest is
$591k 0.17%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $0.0
2025
$6.8m 46.60%
Unlock
2026
$803k 88.21%
Unlock
2027
$1.5m 80.60%
Unlock
2028
$9.9m 582.76%
Unlock

4 Analysts have issued an Prime Medicine EBITDA forecast 2024. The average Prime Medicine EBITDA estimate is

$-211m
Unlock
. This is
4.62% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-190m 5.89%
Unlock
, the lowest is
$-225m 11.45%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-187m 78.55%
2024
$-211m 12.97%
Unlock
2025
$-248m 17.61%
Unlock
2026
$-308m 24.18%
Unlock

EBITDA Margin

2025
-3,640.62% 19.77%
Unlock
2026
-38,352.97% 953.47%
Unlock

5 Prime Medicine Analysts have issued a net profit forecast 2024. The average Prime Medicine net profit estimate is

$-221m
Unlock
. This is
13.61% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-209m 18.31%
Unlock
, the lowest is
$-229m 10.33%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-262m 49.32%
2024
$-221m 15.59%
Unlock
2025
$-202m 8.48%
Unlock
2026
$-193m 4.27%
Unlock
2027
$-182m 6.02%
Unlock
2028
$-175m 3.63%
Unlock

Net Margin

2025
-2,967.46% 37.57%
Unlock
2026
-24,097.79% 712.07%
Unlock
2027
-12,541.07% 47.96%
Unlock
2028
-1,770.14% 85.89%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -2.18 -1.84
49.32% 15.60%
P/E negative
EV/Sales 63.28

5 Analysts have issued a Prime Medicine forecast for earnings per share. The average Prime Medicine <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-1.84
Unlock
. This is
13.62% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-1.74 18.31%
Unlock
, the lowest is
$-1.91 10.33%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-2.18 49.32%
2024
$-1.84 15.60%
Unlock
2025
$-1.68 8.70%
Unlock
2026
$-1.61 4.17%
Unlock
2027
$-1.52 5.59%
Unlock
2028
$-1.46 3.95%
Unlock

P/E ratio

Current -1.63 75.04%
2024
-1.88 15.34%
Unlock
2025
-2.05 9.04%
Unlock
2026
-2.15 4.88%
Unlock
2027
-2.28 6.05%
Unlock
2028
-2.37 3.95%
Unlock

Based on analysts' sales estimates for 2024, the Prime Medicine stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

63.28
Unlock
and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of
89.39
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 498.34
2024
63.28 87.30%
Unlock
2025
43.16 31.79%
Unlock
2026
366.18 748.34%
Unlock
2027
202.77 44.63%
Unlock
2028
29.70 85.35%
Unlock

P/S ratio

Current
2024
89.39 87.30%
Unlock
2025
60.97 31.79%
Unlock
2026
517.24 748.34%
Unlock
2027
286.42 44.63%
Unlock
2028
41.95 85.35%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today